Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years.
Bibliographic Source(s)
National Institute for Health and Clinical Excellence (NICE). Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Oct. 38 p. (Technology appraisal guidance; no. 201).
Guideline Status
This is the current release of the guideline.
full-text:
National Guideline Clearinghouse | Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years.: "Guideline Title
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years. - Enviado mediante la barra Google"
No hay comentarios:
Publicar un comentario